Symeres Acquires DGr Pharma
September 15, 2025
Symeres has acquired DGr Pharma to strengthen its early‑stage drug development and regulatory consultancy capabilities, accelerating IND‑enabling services for biopharma clients. The deal is supported by Keensight Capital, which backs Symeres and aims to expand the platform's integrated CRDMO offering across discovery and early clinical development.
- Buyers
- Symeres, Keensight Capital
- Targets
- DGr Pharma
- Platforms
- Symeres
- Industry
- Healthcare Services
- Location
- Netherlands
- Transaction Type
- Addon
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.